Trial · NCT04625803

Neoadjuvant Therapy for Locally Advanced Colon Cancer

NCT04625803, Phase 2, Completed, Zhejiang University; results first posted 2025-06-17

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Neoadjuvant Therapy for Locally Advanced Colon Cancer. Trials, record NCT04625803. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04625803

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Neoadjuvant Therapy for Locally Advanced Colon Cancer
NCT number: NCT04625803
Status: Completed
Phases: Phase 2
Enrollment: 64 participants, actual
Lead sponsor: Zhejiang University
Conditions: Colon Cancer, Neoadjuvant Therapy
Interventions: Camrelizumab , apatinib and chemotherapy
First posted: 2020-11-12
Last updated: 2025-06-17
Results first posted: 2025-06-17

Source ClinicalTrials.gov

Registered outcomes8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Tumor Regression Rate of MSS/pMMR Patients	2 years	the percentage of tumor regression rate (2-4) in pMMR patients
Secondary	Pathologic Complete Response (pCR) Rates	2 years	Percentage of patients with pathological complete response
Secondary	R0 Resection Rate	2 years	R0 resection accounted for the percentage of all surgical patients=100%
Secondary	The Rate of 2 Year Disease Free Survival (DFS)	2 years	Disease-free survival (DFS) is defined as the time from operation to recurrence of tumor or death. We will evaluate 2 year DFS is 100%
Secondary	Overall Survival (OS)	2 years	Refers to the time of death from enrollment to any cause
Secondary	Event Free Survival (EFS)	2 years	The period from the beginning of neoadjuvant therapy to the occurrence of any of the following events, whichever occurs first: tumor progression as assessed by RECIST 1.1; Tumor recurrence, including local recurrence or distant metastasis; Death from any cause; EFS=100%
Secondary	Perioperative Complication Rate	3 months	The complication rate of all patients during the period around the time of a surgical operation
Secondary	Mortality Rate	2 years	the ratio between deaths and all patients in the study during treatment

Source ClinicalTrials.gov

Outcomes8

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Tumor Regression Rate of MSS/pMMR Patients	2 years	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Pathologic Complete Response (pCR) Rates	2 years
SECONDARY	R0 Resection Rate	2 years
SECONDARY	The Rate of 2 Year Disease Free Survival (DFS)	2 years
SECONDARY	Overall Survival (OS)	2 years
SECONDARY	Event Free Survival (EFS)	2 years
SECONDARY	Perioperative Complication Rate	3 months
SECONDARY	Mortality Rate	2 years	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Tumor Regression Rate of MSS/pMMR Patients	Tumor Regression Grade Rate of pMMR Patients		7		Participants
Mortality Rate	Mortality Rate		0		Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Chemotherapy, PD-1 Inhibitor and Apatinib	64
Overall Study	COMPLETED	Chemotherapy, PD-1 Inhibitor and Apatinib	12
Overall Study	NOT COMPLETED	Chemotherapy, PD-1 Inhibitor and Apatinib	52

Source ClinicalTrials.gov

Adverse events8

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Hypertension	Cardiac disorders	Neutropenia	2	12
other	RCCEP	Cardiac disorders	Neutropenia	8	12
other	Vomiting	Gastrointestinal disorders	Neutropenia	4	12
serious	neutropenia	Blood and lymphatic system disorders	Neutropenia	10	12
serious	decreased white blood cell count	Blood and lymphatic system disorders	Neutropenia	4	12
serious	thrombocytopenia	Blood and lymphatic system disorders	Neutropenia	2	12
serious	hypertension	Blood and lymphatic system disorders	Neutropenia	2	12
serious	ALT increased	Blood and lymphatic system disorders	Neutropenia	2	12

Source ClinicalTrials.gov

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Neutropenia	0	12
Total, other adverse events	Neutropenia	8	12
Total, serious adverse events	Neutropenia	10	12

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
41922688	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04625803

GET https://conductscience.org/api/trials/v1/NCT04625803/registered

API reference For AI assistants